646 filings
S-3
ACHV
Achieve Life Sciences Inc.
Shelf registration
26 Apr 24
4:34pm
ARS
2023 FY
ACHV
Achieve Life Sciences Inc.
26 Apr 24
Annual report to shareholders
4:07pm
DEF 14A
ACHV
Achieve Life Sciences Inc.
Definitive proxy
26 Apr 24
4:05pm
S-8
ACHV
Achieve Life Sciences Inc.
28 Mar 24
Registration of securities for employees
4:47pm
8-K
ACHV
Achieve Life Sciences Inc.
28 Mar 24
Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2023 and Provides Corporate Update
4:06pm
8-K
yjlpft5b4oqow8brz
29 Feb 24
Achieve Life Sciences Announces Pricing of up to $124.2 Million Registered Direct Offering and Concurrent Private Placement
4:41pm
424B5
ktdhysgch7ij
29 Feb 24
Prospectus supplement for primary offering
4:16pm
8-K
73sidqi
11 Dec 23
Other Events
4:04pm
8-K
rgumzugbz
9 Nov 23
Achieve Life Sciences Reports Financial Results for Third Quarter and Provides Corporate Update
4:05pm
8-K
8xl ggn0t3tbtgxp2
14 Aug 23
Achieve Life Sciences Reports Financial Results for Second Quarter 2023 and Provides Corporate Update
4:06pm
EFFECT
mi6cy sagblytvy
26 Jun 23
Notice of effectiveness
12:15am
CORRESP
5arh2p2
21 Jun 23
Correspondence with SEC
12:00am
UPLOAD
h52dr676gc0p4 2hopsn
20 Jun 23
Letter from SEC
12:00am
8-K
6v24rn
9 Jun 23
Amendments to Articles of Incorporation or Bylaws
4:01pm
424B5
1g1d 0hwq
25 May 23
Prospectus supplement for primary offering
4:07pm
8-K
mgn7o lk6urfbwoh
25 May 23
Achieve Life Sciences Announces Pricing of $16.5 Million Registered Direct Offering
9:06am
8-K
2pco9gnjwx9qz3jl lal
23 May 23
Achieve Life Sciences Reports Statistically Significant Smoking Cessation Benefit for Cytisinicline in Second, Confirmatory Phase 3 Clinical Trial
6:13am